In the ALINA phase 3 trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy. Full trial results: nej.md/3VUzf3M

Which are the contemporary approaches to non-metastatic #bladdercancer ?

Join us & discuss with Prof Param Mariappan from Edinburgh Bladder Cancer Surgery (EBCS) in presence or virtually!

Register for free➡️ow.ly/Rtjy50Rc3kE

#IUCS24 Giuseppe Banna Ravindran Kanesvaran

FLAURA2: On-treatment plasma EGFRm clearance prognostic but not predictive benefit with osimertinib + ChemoT vs Osi alone by P.Jänne at #AACR24 Gustave Roussy Dana Farber's EGFR-Mutant Lung Cancer Center Dana-Farber News EGFR Resisters

PSA persistence after radical prostatectomy: Optimal treatment in the case of PSA persistence. Presentation by @profnickjames The ICR. #EAU24 written coverage by Rashid K. Sayyid University of Toronto on UroToday > bit.ly/43UUGnm European Association of Urology (EAU)

Results from KEYNOTE-B99 from Dr. Delvys Rodriguez Abreu at #AACR24 : phase II study in #SCLC of 1L pembrolizumab + EP + either MK-4830 (anti-ILT4), MK-5890 (boserolimab, CD27 agonist), or lenvatinib. RR 65-74% and mPFS 5.5-7.2 months.

⚡️ Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

#BladderCancer #Immunotherapy
Journal of Clinical Oncology

ascopubs.org/doi/pdfdirect/…

Happy to share our commentary about EV-302 European Urology European Association of Urology (EAU) - Thanks to Markus Eckstein Boris Hadaschik Viktor Grünwald

Identification of patients with low or minimal chances of benefiting from EV/P is crucial, as there are other effective therapies available (eg,…

🫁ALINA: Adjuvant alectinib significantly improves 2-year disease-free survival in resected ALK-positive NSCLC patients (stage IB, II, IIIA) vs. platinum-based chemo: 93.8% vs 63.0% (stage II/IIIA) & 93.6% vs 63.7% (ITT).

🫁Highlights potential shift in post-surgery treatment…

66-yr-old, female, PS1, #bladdercancer , T2DM, eGFR 50, had #3 neoadj CisGem, cystectomy, lung/nodal recurrence <12 months (assuming all options available):

Global Cancer Statistics 2022 out by American Cancer Society and IARC 🌐

acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

Global cancer statistics for 2⃣0⃣2⃣2⃣ highlighting significant disparities in incidence rates across world regions

✅Emphasizing the urgent need for targeted prevention strategies to…

🫁 Lung cancer in never-smokers (LCINS) is on the rise! 5th most common cause of cancer-related death!
🫁This highlights the need for new screening 🔎methods to target this distinct disease with unique mutations 🧬 and treatment 💊 needs.
#lungcancer #precisionmedicine …

How to select the correct strategies to personalize the care for advanced #urothelialcarcinoma ?

Join us & discuss with Simon Crabb from ECMC Network Southampton in presence or virtually!

Register for free➡️ow.ly/pMgb50R6xAE

#IUCS24 Giuseppe Banna Ravindran Kanesvaran

Dr. Antoinette Wozniak with an EXCELLENT discussion of the exploding peri-operative space in resectable NSCLC at IASLC Best of #TTLC24 webinar. What will push us toward neoadj vs perioperative? pCR? MRD? impt research questions that need answering.

A very relevant question for 🩸liquid biopsy: Christian Rolfo et al. Icahn School of Medicine at Mount Sinai
🧬When can we trust a negative result from a ctDNA test and omit tissue biopsy?
🧬LB with ctDNA tumor fraction ≥1% accurately identifies true negative results in lung cancer, reducing the need…

🫣Take a peek at the use of PARPi+androgen receptor pathway inhibitors in metastatic castration resistant prostate cancer⁉️

Another terrific paper from Rana McKay Neeraj Agarwal, MD, FASCO Alicia Morgans, MD, MPH and et al.

OncoAlert ESMO - Eur. Oncology

doi.org/10.1016/j.ctrv…

After almost 30 years in medicine, caring for thousands of patients:

Here are the 7 most profound lessons I've learned:
#MedTwitter #medicine

PD-L1 is prognostic but not enough predictive biomarker in metastatic #urothelial carcinoma treated with immune checkpoint inhibitors

Check out this original investigation and meta-analysis by Meet-URO
#oncology #immunotherapy #CancerResearch
jamanetwork.com/journals/jaman…

Celebrating 50 years of Cell with an emblematic article on cancer biomarkers (genomic, immune, circulating, host) led by Solange Peters and Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ . A must-read for your weekend!
🌟FREE link🌟 till 17th May‼️👇
authors.elsevier.com/c/1iqgjL7PXqQ6F

ESMO - Eur. Oncology IASLC ASCO #LCSM …

And posters are up.. thanks again to the great friends who work , support me and often put up with me… Kaushal Parikh Giuseppe Banna Timothée Olivier, MD Maxime Borgeaud Xiuning Le MD PhD #ELCC24 ESMO - Eur. Oncology

Please check this out! It’s important to those interested in the management of resectable NSCLC! IASLC ESMO - Eur. Oncology The ASCO Post Canadian Association of Thoracic Surgeons The Society of Thoracic Surgeons AATS ESTS